Sort
261,768 grants matching “gene therapy”
Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential
$1,000,000Michael Chiu · Kytopen Corp · R44 · FY2025 · AI
Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model
$1,000,000Richard P Junghans · It Bio, Llc · R44 · FY2024 · AI
Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer
$1,000,000Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2022 · CA
A fully integrated assay and platform for detecting Clostridium difficile.
$1,000,000Tanya Marie Ferguson · Claremont Biosolutions, Llc · R44 · FY2014 · AI
Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa
$1,000,000Bin Liu · Venatorx Pharmaceuticals, Inc. · R44 · FY2022 · AI
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma
$1,000,000Evan Charles Unger · Nuvox Pharma, Llc · R44 · FY2022 · CA
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients
$1,000,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders
$1,000,000Henryk Dudek · Dicerna Pharmaceuticals, Inc. · U44 · FY2018 · AA
Comparative Approach to the Hematopoietic Stem Cell
$1,000,000Children'S Hospital Boston · U01 · FY2002 · DK
Human Stem Cell Model of Niemann Pick Type C
$1,000,000Lawrence S Goldstein · University Of California, San Diego · RC1 · FY2010 · NS
Safe and effective anti CD154 antibodies for therapeutic intervention
$1,000,000Jay L Rothstein · Immunext, Inc. · R44 · FY2015 · AI
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders
$1,000,000Henryk Dudek · Dicerna Pharmaceuticals, Inc. · U44 · FY2019 · AA
Sequence-based RNA Fluorescence Assay to Measure Latent HIV Reservoirs
$1,000,000Janet L Huie · Jan Biotech, Inc. · R44 · FY2023 · AI
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI
$1,000,000Saumya Das · Massachusetts General Hospital · UH3 · FY2017 · TR
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease
$1,000,000M. Javad Aman · Abvacc, Inc. · R44 · FY2025 · AI
LIVER PATHOBIOLOGY AND GENE THERAPY RESEARCH CORE CENTER
$1,000,000Yeshiva University · P30 · FY2000 · DK
Type III Secretion Inhibitors for Anti-Infective Therapy
$1,000,000Donald T Moir · Microbiotix, Inc · R44 · FY2011 · AI
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2014 · AI
Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease
$1,000,000Kirk Seward · Mercator Medsystems, Inc. · R44 · FY2024 · HL
Novel Targeted Nanomedicine Delivering MicroRNA-30-5p ReplacementTherapy for Multi-drug Resistant Cancer Treatment
$1,000,000Robert F Place · Mirecule, Inc. · U44 · FY2020 · CA
Transgenic Production of CD4-IgG2 for HIV Therapy
$1,000,000Progenics Pharmaceuticals, Inc. · R44 · FY2003 · AI
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
$1,000,000Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2021 · AI
Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa
$1,000,000Bin Liu · Venatorx Pharmaceuticals, Inc. · R44 · FY2024 · AI
Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias
$1,000,000Peter Galen · Hemex Health, Inc. · R44 · FY2023 · HL
Generation of Induced Pluripotent Stem Cells with Novel Small Molecule Regulator
$1,000,000Young-Sup Yoon · Emory University · RC1 · FY2010 · GM